RELATIVE BIOAVAILABILITY OF DOMESTIC CONTROLLED RELEASE MORPHINE SULPHATE TABLET IN CHINESE VOLUNTEERS

邓艳萍,王凯,刘丽京,孙莉,刘锐克,蔡志基,楼雅卿

DOI: https://doi.org/10.3969/j.issn.1007-9718.2001.04.011

2001-01-01

Abstract:Objective: To study the pharmacokinetics and relative bioavailability of domestic controlled release morphine sulphate tablet. Method: A single oral dose of domestic tablet and MST Continus were given to 19 Chinese healthy volunteers in an open randomized crossover study. The steady-state level of morphine was studied in 27 cancer Chinese patients with sever pain in an open crossover study or parallel controlled trial. The plasma concentration of morphine was determined by GC-MS. Result: After a single dose 30 mg, peak plasma levels (Cmax) of domestic tablet and MST Continus were 14.65 ng·ml-1±s 3.08 ng·ml-1 and 14.71 ng·ml-1±s 2.13 ng·ml-1, Tmax=3.84 h±s 0.50 h and 3.84 h±s 0.37 h, AUC=76.67 ng·h·ml-1±s 8.32 ng·h·ml-1 and 80.06 ng· h· ml-1 ±s 10.89 ng·h·ml-1, respectively. Following multiple doses, Cmin=15.11 ng·ml-1±s 8.98 ng·ml-1 and 12.52 ng·ml-1±s 10.14 ng·ml-1,Cmax=24.06 ng·ml-1±s 11.18 ng· ml-1 and 20.32 ng·ml-1±s 13.18 ng·ml-1, the peak-to-through fluctuation index (FI)was 47.96%±s 19.91% and 46.89%±s 18.77%, respectively. Conclusion: The relative bioavailability of domestic tablet is 96.89%±s 15.33%. There is a bioequivalency in comparison with MST Continus made in England.